Aclaris Therapeutics Stock Market Value
| ACRS Stock | USD 4.32 0.36 9.09% |
| Symbol | Aclaris |
Aclaris Therapeutics Price To Book Ratio
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aclaris Therapeutics. If investors know Aclaris will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aclaris Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.52) | Revenue Per Share 0.381 | Quarterly Revenue Growth (0.53) | Return On Assets (0.19) | Return On Equity (0.26) |
The market value of Aclaris Therapeutics is measured differently than its book value, which is the value of Aclaris that is recorded on the company's balance sheet. Investors also form their own opinion of Aclaris Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aclaris Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aclaris Therapeutics' market value can be influenced by many factors that don't directly affect Aclaris Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aclaris Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aclaris Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aclaris Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Aclaris Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Aclaris Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Aclaris Therapeutics.
| 10/23/2024 |
| 11/22/2024 |
If you would invest 0.00 in Aclaris Therapeutics on October 23, 2024 and sell it all today you would earn a total of 0.00 from holding Aclaris Therapeutics or generate 0.0% return on investment in Aclaris Therapeutics over 30 days. Aclaris Therapeutics is related to or competes with Neogen, Qiagen NV, Sotera Health, RadNet, Myriad Genetics, Biodesix, and Castle Biosciences. Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immun... More
Aclaris Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Aclaris Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Aclaris Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.58 | |||
| Information Ratio | 0.214 | |||
| Maximum Drawdown | 66.9 | |||
| Value At Risk | (5.51) | |||
| Potential Upside | 15.47 |
Aclaris Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Aclaris Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Aclaris Therapeutics' standard deviation. In reality, there are many statistical measures that can use Aclaris Therapeutics historical prices to predict the future Aclaris Therapeutics' volatility.| Risk Adjusted Performance | 0.1807 | |||
| Jensen Alpha | 2.28 | |||
| Total Risk Alpha | 0.9496 | |||
| Sortino Ratio | 0.4758 | |||
| Treynor Ratio | (33.92) |
Aclaris Therapeutics Backtested Returns
Aclaris Therapeutics is dangerous given 3 months investment horizon. Aclaris Therapeutics secures Sharpe Ratio (or Efficiency) of 0.24, which signifies that the company had a 0.24% return per unit of risk over the last 3 months. We were able to interpolate data for thirty different technical indicators, which can help you to evaluate if expected returns of 2.42% are justified by taking the suggested risk. Use Aclaris Therapeutics Risk Adjusted Performance of 0.1807, mean deviation of 5.18, and Downside Deviation of 4.58 to evaluate company specific risk that cannot be diversified away. Aclaris Therapeutics holds a performance score of 18 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of -0.0671, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Aclaris Therapeutics are expected to decrease at a much lower rate. During the bear market, Aclaris Therapeutics is likely to outperform the market. Use Aclaris Therapeutics downside variance, and the relationship between the sortino ratio and accumulation distribution , to analyze future returns on Aclaris Therapeutics.
Auto-correlation | 0.79 |
Good predictability
Aclaris Therapeutics has good predictability. Overlapping area represents the amount of predictability between Aclaris Therapeutics time series from 23rd of October 2024 to 7th of November 2024 and 7th of November 2024 to 22nd of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Aclaris Therapeutics price movement. The serial correlation of 0.79 indicates that around 79.0% of current Aclaris Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.79 | |
| Spearman Rank Test | 0.64 | |
| Residual Average | 0.0 | |
| Price Variance | 0.79 |
Aclaris Therapeutics lagged returns against current returns
Autocorrelation, which is Aclaris Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Aclaris Therapeutics' stock expected returns. We can calculate the autocorrelation of Aclaris Therapeutics returns to help us make a trade decision. For example, suppose you find that Aclaris Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Aclaris Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Aclaris Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Aclaris Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Aclaris Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
Aclaris Therapeutics Lagged Returns
When evaluating Aclaris Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Aclaris Therapeutics stock have on its future price. Aclaris Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Aclaris Therapeutics autocorrelation shows the relationship between Aclaris Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in Aclaris Therapeutics.
Regressed Prices |
| Timeline |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Aclaris Stock Analysis
When running Aclaris Therapeutics' price analysis, check to measure Aclaris Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aclaris Therapeutics is operating at the current time. Most of Aclaris Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aclaris Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aclaris Therapeutics' price. Additionally, you may evaluate how the addition of Aclaris Therapeutics to your portfolios can decrease your overall portfolio volatility.